Alejandro R Chade

List of Publications by Year in Descending Order

59 papers	1,817 citations	22 h-index	42 g-index
185 ext. papers	2,083 ext. citations	5.5 avg, IF	4.91 L-index

#	Paper	IF	Citations
59	Renal mitochondrial injury in the pathogenesis of CKD: mtDNA and mitomiRs.. *Clinical Science*, **2022**, 136, 345-360	6.5	0
58	Renal Ischemia Induces Epigenetic Changes in Apoptotic, Proteolytic, and Mitochondrial Genes in Swine Scattered Tubular-like Cells. *Cells*, **2022**, 11, 1803	7.9	0
57	A dose-escalating toxicology study of the candidate biologic ELP-VEGF. *Scientific Reports*, **2021**, 11, 6216	4.9	2
56	Delayed Systemic Treatment with Cannabinoid Receptor 2 Agonist Mitigates Spinal Cord Injury-Induced Osteoporosis More Than Acute Treatment Directly after Injury. *Neurotrauma Reports*, **2021**, 2, 270-284	1.6	0
55	Renal Revascularization Attenuates Myocardial Mitochondrial Damage and Improves Diastolic Function in Pigs with Metabolic Syndrome and Renovascular Hypertension. *Journal of Cardiovascular Translational Research*, **2021**, 1	3.3	0
54	Intrarenal modulation of NF-Β activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis. *American Journal of Physiology - Renal Physiology*, **2021**, 321, F411-F423	4.3	0
53	Recovery of Renal Function following Kidney-Specific VEGF Therapy in Experimental Renovascular Disease. *American Journal of Nephrology*, **2020**, 51, 891-902	4.6	4
52	Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-Β improves renal recovery in chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2020**, 319, F139-F148	4.3	5
51	A Boolean Model of Microvascular Rarefaction to Predict Treatment Outcomes in Renal Disease. *Scientific Reports*, **2020**, 10, 440	4.9	2
50	DETERMINING THE EFFECTS OF PRO-ANGIOGENIC ELP-VEGF THERAPY ON TUMOR GROWTH AND PROGRESSION. *FASEB Journal*, **2020**, 34, 1-1	0.9	
49	Intrarenal Renin Angiotensin System Imbalance During Postnatal Life Is Associated With Increased Microvascular Density in the Mature Kidney. *Frontiers in Physiology*, **2020**, 11, 1046	4.6	1
48	Macrophage polarization in chronic kidney disease: a balancing act between renal recovery and decline?. *American Journal of Physiology - Renal Physiology*, **2019**, 317, F1409-F1413	4.3	18
47	Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization. *American Journal of Physiology - Renal Physiology*, **2019**, 316, F1016-F1025	4.3	10
46	Targeted VEGF (Vascular Endothelial Growth Factor) Therapy Induces Long-Term Renal Recovery in Chronic Kidney Disease via Macrophage Polarization. *Hypertension*, **2019**, 74, 1113-1123	8.5	25
45	Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer. *Pharmaceutics*, **2019**, 11,	6.4	6
44	VEGF Therapy Shifts Macrophage Phenotype and Improves Renal Recovery in Chronic Kidney Disease. *FASEB Journal*, **2019**, 33, 863.12	0.9	
43	Bioengineered VEGF Therapy Following Angioplasty in Renovascular Disease: More and Better Microvessels. *FASEB Journal*, **2019**, 33, 863.4	0.9	

42	Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease. *Kidney International*, **2018**, 93, 842-854	9.9	22
41	VEGF therapy for the kidney: emerging strategies. *American Journal of Physiology - Renal Physiology* , **2018**, 315, F747-F751	4.3	8
40	A translational model of chronic kidney disease in swine. *American Journal of Physiology - Renal Physiology*, **2018**, 315, F364-F373	4.3	19
39	Translational Traits of a Swine Model of CKD: Inflammation. *FASEB Journal*, **2018**, 32, 851.10	0.9	
38	A Boolean Model of Microvascular Rarefaction to Predict Renal Outcomes in Renovascular Disease. *FASEB Journal*, **2018**, 32, 851.6	0.9	
37	SaO031THERAPEUTIC ANGIOGENESIS PROMOTES RENAL RECOVERY IN CKD PARTLY BY SHIFTING MACROPHAGE PHENOTYPE. *Nephrology Dialysis Transplantation*, **2018**, 33, i328-i328	4.3	
36	Molecular Size Modulates Pharmacokinetics, Biodistribution, and Renal Deposition of the Drug Delivery Biopolymer Elastin-like Polypeptide. *Scientific Reports*, **2018**, 8, 7923	4.9	17
35	Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury. *Hypertension*, **2017**, 69, 551-563	8.5	14
34	A kidney-selective biopolymer for targeted drug delivery. *American Journal of Physiology - Renal Physiology*, **2017**, 312, F54-F64	4.3	39
33	Enhanced maximal exercise capacity, vasodilation to electrical muscle contraction, and hind limb vascular density in ASIC1a null mice. *Physiological Reports*, **2017**, 5, e13368	2.6	4
32	Role of the Renal Microcirculation in Progression of Chronic Kidney Injury in Obesity. *American Journal of Nephrology*, **2016**, 44, 354-367	4.6	20
31	Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1741-52	12.7	37
30	MO049A NOVEL BIOPOLYMER-DELIVERED VEGF FOR THERAPEUTIC ANGIOGENESIS IN RENOVASCULAR DISEASE: TARGETING THE KIDNEY VIA SYSTEMIC ADMINISTRATION. *Nephrology Dialysis Transplantation*, **2016**, 31, i50-i50	4.3	
29	Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease. *Nephrology Dialysis Transplantation*, **2015**, 30, 584-93	4.3	12
28	Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 1071-80	12.7	19
27	Nephron Deficiency and Predisposition to Renal Injury in a Novel One-Kidney Genetic Model. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 1634-46	12.7	20
26	Systemic Administration of a Biopolymer-delivered VEGF Improved Renal Hemodynamics and Microvascular Rarefaction in Renal Artery Stenosis. *FASEB Journal*, **2015**, 29, 808.17	0.9	
25	Potential Mechanisms of Renoprotection in the Stenotic Kidney After Endothelin-type A Receptor Antagonism: Podocytes, VEGF and sFlt-1. *FASEB Journal*, **2015**, 29, 664.2	0.9	

24	A Kidney-targeted Protein Biopolymer Drug Delivery System. *FASEB Journal*, **2015**, 29, 967.5	0.9	
23	Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease. *Kidney International*, **2014**, 85, 833-44	9.9	25
22	Renal vascular structure and rarefaction. *Comprehensive Physiology*, **2013**, 3, 817-31	7.7	69
21	Renoprotective effects of hepatocyte growth factor in the stenotic kidney. *American Journal of Physiology - Renal Physiology*, **2013**, 304, F625-33	4.3	25
20	Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?. *Journal of the American Society of Hypertension*, **2013**, 7, 180-90		6
19	Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 1006-13	9.4	44
18	Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. *American Journal of Physiology - Renal Physiology*, **2012**, 302, F308-15	4.3	43
17	Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach. *American Journal of Physiology - Renal Physiology*, **2012**, 302, F1342-50	4.3	56
16	Treatment with C-peptide slows the progression of diabetic renal disease in the streptozotocin (STZ)-induced diabetic rat. *FASEB Journal*, **2011**, 25, 664.2	0.9	
15	Renal microvascular disease determines the responses to revascularization in experimental renovascular disease. *Circulation: Cardiovascular Interventions*, **2010**, 3, 376-83	6	54
14	Endothelial progenitor cells homing and renal repair in experimental renovascular disease. *Stem Cells*, **2010**, 28, 1039-47	5.8	95
13	Microvascular rarefaction precedes the decline in renal function in the streptozotocin (STZ)-induced diabetic rat. *FASEB Journal*, **2010**, 24, 812.3	0.9	
12	Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. *Circulation*, **2009**, 119, 547-57	16.7	178
11	Simvastatin abates development of renal fibrosis in experimental renovascular disease. *Journal of Hypertension*, **2008**, 26, 1651-60	1.9	49
10	Obesity Increases Renal Cortical Neovascularization in Zucker Rats. *FASEB Journal*, **2008**, 22, 947.7	0.9	
9	Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT. *Radiology*, **2007**, 243, 405-12	20.5	102
8	Kidney in early atherosclerosis. *Hypertension*, **2005**, 45, 1042-9	8.5	120
7	Antioxidant intervention blunts renal injury in experimental renovascular disease. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 958-66	12.7	103

6	Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 1816-25	12.7	66
5	Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. *Kidney International*, **2003**, 64, 962-9	9.9	38
4	Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. *American Journal of Hypertension*, **2003**, 16, 111-5	2.3	21
3	Beneficial effects of antioxidant vitamins on the stenotic kidney. *Hypertension*, **2003**, 42, 605-12	8.5	59
2	Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1295-301	9.4	135
1	Distinct renal injury in early atherosclerosis and renovascular disease. *Circulation*, **2002**, 106, 1165-71	16.7	204